Genomics and pharmacogenomics of brain disorders

Current Pharmaceutical Biotechnology

Volumn 13, Issue 5, 2012, Pages 674-725

  Cacabelos, Ramón ^a   Martínez Bouza, Rocío ^a   Carril, Juan Carlos ^a   Fernández Novoa, Lucía ^a   Lombardi, Valter ^a   Carrera, Iván ^a   Corzo, Lola ^a   McKay, Adam ^a  

^a CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

Antidepressants; APOB; APOC3; APOE; CYP2C19; CYP2C9; CYP2D6; CYP3A4 5; Dementia; Mental disorders; Neuroleptics; Pharmacogenomics

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARIPIPRAZOLE; BENPERIDOL; BENZODIAZEPINE; BROMPERIDOL; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DONEPEZIL; DROPERIDOL; FLUPHENAZINE; HYPNOTIC SEDATIVE AGENT; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BRAIN DISEASE; COPY NUMBER VARIATION; DEPRESSION; DNA SEQUENCE; DRUG DISPOSITION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE DELETION; HUMAN; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; PHARMACOGENOMICS; POINT MUTATION; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PROTEOMICS; SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM;

BRAIN DISEASES; GENOMICS; HUMANS; METABOLOMICS; PHARMACOGENETICS; PROTEOMICS;

EID: 84860271446     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799857576     Document Type: Article

References (233)

1. Ruff, C. T.; Braunwald, E. The evolving epidemiology of acute coronary syndromes. Nat. Rev. Cardiol., 2010, 8 (3), 140-147.
2. Centers for Disease Control and Prevention. Available at: http://cdc.gov/nchs/Default.htm (Accessed Dec 29, 2010).
3. Sousa, R. M.; Ferri, C. P.; Acosta, D.; Albanese, E.; Guerra, M.; Huang, Y.; Jacob, K. S.M.; Jotheeswaran, A. T.; Llibre Rodriguez, J. J.; Rodriguez Pichardo, G.; Calvo Rodriguez, M.; Salas, A.; Sosa, A. L.; Williams, J.; Zuniga, T.; Prince, M. Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population- based survey. Lancet, 2009, 374, 1821-1830.
4. Herrmann, N.; Tam, D. Y.; Balshaw, R.; Sambrook, R.; Lesnikova, N.; Lanctôt, K. L.; The Canadian Outcomes Study in Dementia (COSID) Investigators. The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada. Can. J. Psychiatry, 2010, 55 (12), 768-775.
5. Cacabelos, R. The path to personalized medicine in mental disorders. In: The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes, Ritsner, M. S. Eds., Springer, Netherlands, 4, 3-63, 2009.
6. Birnbaum, H. G.; White, A. G.; Reynolds, J. L.; Greenberg, P. E.; Zhang, M.; Vallow, S.; Schein, J. R.; Katz, N. P. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin. J. Pain, 2006, 22, 667-676.
7. Amundsen, M. O.; Engdahl, B.; Berg C.; Nordeng, H. Use of psychotropic drugs and analgesics among users of antiobesity drugs-a population based study. Pharmacoepidemiol. Drug Saf., 2010, 19 (3), 273-279.
8. Essock, S. M.; Covell, N. H.; Leckman-Westin, E.; Lieberman, J. A.; Sederer, L. I.; Kealey, E.; Finnerty, M, T. Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New York state. Psychiatr. Serv., 2009, 60 (12), 1595-1602.
9. Acquaviva, E.; Legleye, S.; Auleley, G. R.; Deligne, J.; Carel, D.; Falissard, B. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry, 2009, 9, 72.
10. Trifirò, G.; Sini, G.; Sturkenboom, M. C.; Vanacore, N.; Mazzaglia, G.; Caputi, A. P.; Cricelli, C.; Brignoli, O.; Aguglia, E.; Biggio, G.; Samani, F. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia. Int. Clin. Psychopharmacol., 2010, 25 (1), 22-28.
11. Seitz, D. P.; Gruneir, A.; Conn, D. K.; Rochon, P. A. Cholinesterase Inhibitor Use in U.S. Nursing Homes: Results from the National Nursing Home Survey. J. Am. Geriatr. Soc., 2009, 57 (12), 2269-2274.
12. Kamble, P.; Chen, H.; Sherer, J. T.; Aparasu, R. R. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of national survey data. Drugs Aging, 2009, 26 (6), 483-492.
13. Jano, E.; Johnson, M.; Chen, H.; Aparasu, R. R. Determinants of atypical antipsychotic use among antipsychotic users in community- dwelling elderly, 1996-2004. Curr. Med. Res. Opin., 2008, 24 (3), 709-716.
14. Liperoti, R.; Onder, G.; Landi, F.; Lapane, K. L.; Mor, V.; Bernabei, R.; Gambassi, G. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J. Clin. Psychiatry, 2009, 70 (10) 1340-1347.
15. French, D. D.; Campbell, R.; Spehar, A.; Cunningham, F.; Bulat T.; Luther, S. L. Drugs and falls in community-dwelling older people: a national veterans study. Clin. Ther., 2006, 28 (4), 619-630.
16. Nishtala, P. S.; McLachlan, A. J.; Bell J. S.; Chen, T. F. Determinants of antidepressant medication prescribing in elderly residents of aged care homes in Australia: a retrospective study. Am. J. Geriatr. Pharmacother., 2009, 7 (4) 210-219.
17. Aparasu, R. R.; Jano, E.; Bhatara, V. Concomitant antipsychotic prescribing in US outpatient settings. Res. Social Adm. Pharm., 2009, 5 (3), 234-241.
18. Sankaranarayanan, J.; Puumala, S. E. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clin. Ther., 2007, 29 (4), 723-741.
19. Baandrup, L.; Gasse, C.; Jensen, V. D.; Glenthoj, B. Y.; Nordentoft, M.; Lublin, H.; Fink-Jensen, A.; Lindhardt, A.; Mortensen, P. B. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a populationbased nested case-control study. J. Clin. Psychiatry, 2010, 71 (2), 103-108.
20. Moore, M.; Yuen, H. M.; Dunn, N.; Mullee, M. A.; Maskell, J.; Kendrick, T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ, 2009, 339, b3999.
21. Degner, D.; Grohmann, R.; Kropp, S.; Rüther, E.; Bender, S.; Engel, R. R.; Schmidt, L. G. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry, 2004, 37 (Suppl 1), S39-45.
22. Cacabelos, R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev. Mol. Diag., 2009, 9 (6), 567-611.
23. Anderson, C. N. G.; Grant, S. G. N. High throughput protein expression screening in the nervous system-needs and limitations. J. Physiol., 2006, 575 (2), 367-372.
24. Xu, X.; Zhan, M.; Duan, W.; Prabhu, V.; Brenneman, R.; Wood, W.; Firman, J.; Li, H.; Zhang, P.; Ibe, C.; Zonderman, A. B.; Longo, D. L.; Poosala, S.; Becker, K. G.; Mattson, M. P. Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender. Genome Biol., 2007, 8 (11), R234.
25. Cacabelos, R.; Fernández-Novoa, L.; Martínez-Bouza, R.; McKay, A.; Carril, J. C.; Lombardi, V.; Corzo, L.; Carrera, I.; Tellado, I.; Nebril, L.; Alcaraz, M.; Rodríguez, S.; Casas, Á.; Couceiro, V.; Álvarez, A. Future trends in the pharmacogenomics of brain disorders and dementia: influence of APOE and CYP2D6 variants. Pharmaceuticals, 2010, 3 (10), 3040-3100.
26. Cacabelos, R.; Martínez-Bouza, R. Genomics and Pharmacogenomics of Schizophrenia. CNS Neurosci. Ther., 2011, 17 (5), 541-565.
27. International Union of Basic and Clinical Pharmacology. http://www.iuphar-db.org. (Accessed Sept 25, 2010).
28. Sharp, A. J.; Cheng, Z.; Eichler, E. E. Structural variation of human genome. Annu. Rev. Genomics Hum. Genet., 2006, 7, 407-442.
29. Crawford, D. C.; Akey, D. T.; Nickerson, D. A. The patterns of natural variation in human genes. Annu. Rev. Genomics Hum. Genet., 2005, 6, 287-312.
30. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/omim.
31. Cacabelos, R.; Fernández-Novoa L.; Lombardi V.; Kubota Y.; Takeda M. Molecular genetics of Alzheimer's disease and aging. Meth. Find. Exper. Clin. Pharmacol., 2005, 27 (Suppl A), 1-573.
32. The Alzheimer Research Forum. Available at: http: //www.alzgene.org.
33. Selkoe, D. J.; Podlisny, M. B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet., 2005, 3, 67-99.
34. Suh, Y. H.; Checler, F. Amyloid precursor protein, presenilins, and α-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev., 2002, 54 (3), 469-525.
35. Cacabelos, R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat., 2007, 3 (3), 303-333.
36. Cacabelos, R.; Martínez-Bouza, R. Genomics and pharmacogenomics of dementia. CNS Neurosci. Ther., 2011, 17 (5), 566-576.
37. Lichtenstein, P.; Yip, B. H.; Björk, C.; Pawitan, Y.; Cannon, T. D.; Sullivan, P. F.; Hultman, C. M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population- based study. Lancet, 2009, 373 (9659), 234-239.
38. Wiener, H. W.; Klei, L.; Irvin, M. D.; Perry, R. T.; Aliyu, M. H.; Allen, T. B.; Bradford, L. D.; Calkins, M. E.; Devlin, B.; Edwards, N.; Gur, R. E.; Gur, R. C.; Kwentus, J.; Lyons, P. D.; McEvoy, J. P.; Nasrallah, H. A.; Nimgaonkar, V. L.; O'Jile, J.; Santos, A. B.; Savage, R. M.; Go, R. C. Linkage analysis of schizophrenia in African- American families. Schizophr. Res., 2009, 109 (1-3), 70-79.
39. Holmans, P. A.; Riley, B.; Pulver, A. E.; Owen, M. J.; Wildenauer, D. B.; Gejman, P. V.; Mowry, B. J.; Laurent, C.; Kendler, K. S.; Nestadt, G.; Williams, N. M.; Schwab, S. G.; Sanders, A. R.; Nertney, D.; Mallet, J.; Wormley, B.; Lasseter, V. K.; O'Donovan, M. C.; Duan, J.; Albus, M.; Alexander, M.; Godard, S.; Ribble, R.; Liang, K. Y.; Norton, N.; Maier, W.; Papadimitriou, G.; Walsh, D.; Jay, M.; O'Neill, A.; Lerer, F. B.; Dikeos, D.; Crowe, R, R.; Silverman, J. M.; Levinson, D. F. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol. Psychiatry, 2009, 14 (8), 786-795.
40. Escamilla, M.; Hare, E.; Dassori, A. M.; Peralta, J. M.; Ontiveros, A.; Nicolini, H.; Raventós, H.; Medina, R.; Mendoza, R.; Jerez, A.; Muñoz, R.; Almasy, L. A schizophrenia gene locus on chromosome 17q21 in a new set of families of Mexican and Central American ancestry: evidence from the NIMH Genetics of schizophrenia in latino populations study. Am. J. Psychiatry, 2009, 166 (4), 442-449.
41. Mefford, H. C.; Eichler, E.E. Duplication hotspots, rare genomic disorders, and common disease. Curr. Opin. Genet. Dev., 2009, 19 (3), 196-204.
42. Sun, J.; Han, L.; Zhao, Z. Gene-and evidence-based candidate gene selection for schizophrenia and gene feature analysis. Artif. Intell. Med., 2010, 48 (2), 99-106.
43. Le Strat, Y.; Ramoz, N.; Gorwood, P. The role of genes involved in neuroplasticity and neurogenesis in the observation of a geneenvironment interaction (GxE) in schizophrenia. Curr. Mol. Med., 2009, 9 (4), 506-518.
44. Jönsson, E. G.; Saetre, P.; Vares, M.; Andreou, D.; Larsson, K.; Timm, S.; Rasmussen, H. B.; Djurovic, S.; Melle, I.; Andreassen, O. A.; Agartz, I.; Werge, T.; Hall, H.; Terenius, L. DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. Neuropsychobiology, 2009, 59 (3), 142-150.
45. Psychiatric GWAS Consortium Coordinating Committee.; Cichon, S.; Craddock, N.; Daly, M.; Faraone, S. V.; Gejman, P. V.; Kelsoe, J.; Lehner, T.; Levinson, D. F.; Moran, A.; Sklar, P.; Sullivan, P. F. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am. J. Psychiatry, 2009, 166 (5), 540-556.
46. Psychiatric GWAS Consortium Steering Committee. A framework for interpreting genome-wide association studies of psychiatric disorders. Mol. Psychiatry, 2009, 14 (1), 10-17.
47. O'Donovan, M. C.M Craddock, N. J.; Owen, M. J. Genetics of psychosis; insights from views across the genome. Hum. Genet., 2009, 126, 3-12.
48. Ng, M.Y.; Levinson, D. F.; Faraone, S. V.; Suarez, B. K.; DeLisi, L. E.; Arinami, T.; Riley, B.; Paunio, T.; Pulver, A. E.; Irmansyah, I.; Holmans, P. A.; Escamilla, M.; Wildenauer, D. B.; Williams, N. M.; Laurent, C.; Mowry, B. J.; Brzustowicz, L. M.; Maziade, M.; Sklar, P.; Garver, D. L.; Abecasis, G. R.; Lerer, B.; Fallin, M. D.; Gurling, H. M.; Gejman, P. V.; Lindholm, E.; Moises, H. W.; Byerley, W., Wijsman, E. M.; Forabosco, P.; Tsuang, M. T.; Hwu, H. G.; Okazaki, Y.; Kendler, K. S.; Wormley, B.; Fanous, A.; Walsh, D.; O'Neill, F. A.; Peltonen, L.; Nestadt, G.; Lasseter, V. K.; Liang, K. Y.; Papadimitriou, G. M.; Dikeos, D. G.; Schwab, S. G.; Owen, M. J.; O'Donovan, M. C.; Norton, N.; Hare, E.; Raventos, H.; Nicolini, H.; Albus, M.; Maier, W.; Nimgaonkar, V. L.; Terenius, L.; Mallet, J.; Jay, M.; Godard, S.; Nertney, D.; Alexander, M.; Crowe, R R.; Silverman, J. M.; Bassett, A. S.; Roy, M. A.; Mérette, C.; Pato, C. N.; Pato, M. T.; Roos, J. L.; Kohn, Y.; Amann-Zalcenstein, D.; Kalsi, G.; McQuillin, A.; Curtis, D.; Brynjolfson, J.; Sigmundsson, T.; Petursson, H.; Sanders, A. R.; Duan, J.; Jazin, E.; Myles-Worsley, M.; Karayiorgou, M.; Lewis, C. M. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol. Psychiatry, 2009, 14 (8), 774-785.
49. Moskvina, V.; Craddock, N.; Holmans, P.; Nikolov, I.; Pahwa, J. S.; Green, E.; Wellcome Trust Case Control Consortium.; Owen M. J.; O'Donovan M.C. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol. Psychiatry, 2009, 14, 252-260.
50. Yurov, Y. B.; Iourov, I. Y.; Vorsanova, S. G.; Liehr, T.; Kolotii, A. D.; Kutsev, S. I.; Pellestor, F.; Beresheva, A. K.; Demidova, I. A.; Kravets, V. S.; Monakhov, V. V.; Soloviev, I. V. Aneuploidy and confined chromosomal mosaicism in the developing human brain. PLoS One, 2007, 2 (6), e558.
51. Iourov, I. Y.; Vorsanova, S. G.; Liehr, T.; Yurov, Y. B. Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol. Dis., 2009, 34 (2), 212-220.
52. Yurov, Y. B.; Iourov, I. Y.; Vorsanova, S. G.; Demidova, I. A.; Kravetz, V. S.; Beresheva, A. K.; Kolotii, A. D.; Monakclov, V. V.; Uranova, N. A.; Vostrikov, V. M.; Soloviev, L. V.; Liehr, T. The schizophrenia brain exhibits low-level aneuploidy involving chromosome 1. Schizophr. Res., 2008, 98 (1), 139-147.
53. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature, 2008, 455 (7210), 237-241.
54. Ikeda, M.; Aleksic, B.; Kirov, G.; Kinoshita, Y.; Yamanouchi, Y.; Kitajima, T.; Kawashima, K.; Okochi, T.; Kishi, T.; Zaharieva, I.; Owen, M. J.; O'Donovan, M. C.; Ozaki, N.; Iwata, N. Copy number variation in schizophrenia in the Japanese population. Biol. Psychiatry, 2010, 67 (3), 283-286.
55. Stefansson, H.; Rujescu, D.; Cichon, S.; Pietiläinen, O. P.; Ingason, A.; Steinberg, S.; Fossdal, R.; Sigurdsson, E.; Sigmundsson, T.; Buizer-Voskamp, J. E.; Hansen, T.; Jakobsen, K. D.; Muglia, P.; Francks, C.; Matthews, P. M.; Gylfason, A.; Halldorsson, B. V.; Gudbjartsson, D.; Thorgeirsson, T. E.; Sigurdsson, A.; Jonasdottir, A.; Bjornsson, A.; Mattiasdottir, S.; Blondal, T.; Haraldsson, M.; Magnusdottir, B. B.; Giegling, I.; Möller, H. J.; Hartmann, A.; Shianna, K.V.; Ge, D.; Need, A. C.; Crombie, C, Fraser, G, Walker, N, Lonnqvist, J, Suvisaari, J, Tuulio-Henriksson, A.; Paunio, T.; Toulopoulou, T.; Bramon, E.; Di Forti, M.; Murray, R.; Ruggeri, M.; Vassos, E.; Tosato, S.; Walshe, M.; Li, T.; Vasilescu, C.; Mühleisen, T. W.; Wang, A. G.; Ullum, H.; Djurovic, S.; Melle, I.; Olesen, J.; Kiemeney, L. A.; Franke, B.; GROUP.; Sabatti, C.; Freimer, N. B.; Gulcher, J. R.; Thorsteinsdottir, U.; Kong, A.; Andreassen, O. A.; Ophoff, R. A.; Georgi, A.; Rietschel, M.; Werge, T.; Petursson, H.; Goldstein, D. B.; Nöthen, M. M.; Peltonen, L.; Collier, D. A.; St Clair, D. Stefansson, K. Large recurrent microdeletions associated with schizophrenia. Nature, 2008, 455 (7210), 232-236.
56. Tabarés-Seisdedos, R.; Rubenstein, J. L. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol. Psychiatry, 2009, 14 (6), 563-589.
57. Need, A. C.; Ge, D.; Weale, M. E.; Maia, J.; Feng, S.; Heinzen, E. L.; Shianna, K. V.; Yoon, W.; Kasperaviciute, D.; Gennarelli, M.; Strittmatter, W. J.; Bonvicini, C.; Rossi, G.; Jayathilake, K.; Cola, P. A.; McEvoy, J. P.; Keefe, R. S.; Fisher, E. M.; St Jean, P. L.; Giegling, I.; Hartmann, A. M.; Möller, H. J.; Ruppert, A.; Fraser, G.; Crombie, C.; Middleton, L. T.; St Clair, D.; Roses, A. D.; Muglia, P.; Francks, C.; Rujescu, D.; Meltzer, H. Y. Goldstein, D. B. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet., 2009, 5 (2), e1000373.
58. Kirov, G.; Grozeva, D.; Norton, N.; Ivanov, D.; Mantripragada, K. K.; Holmans, P.; International Schizophrenia Consortium; the Wellcome Trust Case Control Consortium; Craddock, N.; Owen, M. J. O'Donovan, M. C. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum. Mol. Genet., 2009, 18 (8), 1497-1503.
59. Maziade, M.; Chagnon, Y. C.; Roy, M. A.; Bureau, A.; Fournier, A; Mérette, C. Chromosome 13q13-q14 locus overlaps mood and psychotic disorders: the relevance for redefining phenotype. Eur. J. Hum. Genet., 2009, 17 (8), 1034-1042.
60. de Kovel, C. G.; Trucks, H.; Helbig, I.; Mefford, H. C.; Baker, C.; Leu, C.; Kluck, C.; Muhle, H.; von Spiczak, S.; Ostertag, P.; Obermeier, T.; Kleefuss-Lie, A. A.; Hallmann, K.; Steffens, M.; Gaus, V.; Klein, K. M.; Hamer, H. M.; Rosenow, F.; Brilstra, E. H.; Trenité, D. K.; Swinkels, M. E.; Weber, Y. G.; Unterberger, I.; Zimprich, F.; Urak, L.; Feucht, M.; Fuchs, K.; Møller, R. S.; Hjalgrim, H.; De Jonghe, P.; Suls, A.; Rückert, I. M.; Wichmann, H. E.; Franke, A.; Schreiber, S.; Nürnberg, P.; Elger, C. E.; Lerche, H.; Stephani, U.; Koeleman, B. P.; Lindhout, D.; Eichler, E. E.; Sander, T. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain, 2010, 133 (Pt 1), 23-32.
61. Dibbens, L. M.; Mullen, S.; Helbig, I.; Mefford H. C.; Bayly, M. A.; Bellows, S.; Leu, C.; Trucks, H.; Obermeier, T.; Wittig, M.; Franke, A.; Caglayan, H.; Yapici, Z.; EPICURE Consortium, Sander, T.; Eichler, E. E.; Scheffer, I. E.; Mulley, J. C.; Berkovic, S. F. Familial and sporadic 15q13.3 microdeletions in idiopathic generalized epilepsy: precedent for disorders with complex inheritance. Hum, Mol, Genet., 2009, 18 (19), 3626-3631.
62. Ben-Shachar S. B.; Lanpher, B.; German J. R.; Qasaymeh, M.; Potocki, L.; Sreenath Nagamani, S.C.; Franco, L. M.; Malphrus, A.; Bottenfield, G. W.; Spence, J. E.; Amato, S.; Rousseau, J. A.; Moghaddam, B.; Skinner, C.; Skinner, S. A.; Bernes, S.; Armstrong, N.; Shinawi, M.; Stankiewicz, P.; Patel, A.; Cheung, SW.; Lupski, J. R.; Beaudet, A. L.; Sahoo, T. Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J. Med. Genet., 2009, 46, 382-388.
63. Leonard, S.; Freedman, R. Genetics of chromosome 15q13-q14 in schizophrenia. Biol. Psychiatry, 2006, 60 (2), 115-122.
64. Pagnamenta, A. T.; Wing, K.; Akha, E. S.; Knight, S. J.; Bölte, S.; Schmötzer, G.; Duketis, E.; Poustka, F.; Klauck, S. M.; Poustka, A.; Ragoussis, J.; Bailey, A. J.; Monaco, A. P. International Molecular Genetic Study of Autism Consortium. A 15q13.3 microdeletion segregating with autism. Eur. J. Hum. Genet., 2009, 17 (5), 687-692.
65. Ingason, A.; Rujescu, D.; Cichon, S.; Sigurdsson, E.;, Sigmundsson, T.; Pietiläinen, O. P.; Buizer-Voskamp, J. E.; Strengman, E.; Francks, C.; Muglia, P.; Gylfason, A.; Gustafsson, O.; Olason, P. I.; Steinberg, S.; Hansen, T.; Jakobsen, K. D.; Rasmussen, H. B.; Giegling, I.; Möller, H. J.; Hartmann, A.; Crombie, C.; Fraser, G.; Walker, N.; Lonnqvist, J.; Suvisaari, J.; Tuulio-Henriksson, A.; Bramon, E.; Kiemeney, L. A.; Franke, B.; Murray, R.; Vassos, E.; Toulopoulou, T.; Mühleisen, T. W.; Tosato, S.; Ruggeri, M.; Djurovic, S.; Andreassen, O. A.; Zhang, Z.; Werge, T.; Ophoff, R. A.; GROUP Investigators, Rietschel, M.; Nöthen, M. M.; Petursson, H.; Stefansson, H.; Peltonen, L.; Collier, D.; Stefansson, K.; Clair, D. M. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol. Psychiatry, 2011, 16 (1), 17-25.
66. Jolin, E. M.; Weller, R. A.; Weller, E. B. Psychosis in children with velocardiofacial syndrome (22q11.2 deletion syndrome). Curr. Psychiatry Rep., 2009, 11 (2), 99-105.
67. Shashi, V.; Kwapil, T. R.; Kaczorowski, J.; Berry, M. N.; Santos, C. S.; Howard, T. D.; Goradia, D.; Prasad, K.; Vaibhav, D.; Rajarethinam, R.; Spence, E.; Keshavan, M. S. Evidence of gray matter reduction and dysfunction in chromosome 22q11.2 deletion syndrome. Psychiatry Res., 2010, 181 (1), 1-8.
68. Guilmatre, A.; Dubourg, C.; Mosca, A. L.; Legallic, S.; Goldenberg, A.; Drouin-Garraud, V.; Layet, V.; Rosier, A.; Briault, S.; Bonnet-Brilhault, F.; Laumonnier, F.; Odent, S.; Le Vacon, G.; Joly-Helas, G.; David, V.; Bendavid, C.; Pinoit, J. M.; Henry, C.; Impallomeni, C.; Germano, E.; Tortorella, G.; Di Rosa, G.; Barthelemy, C.; Andres, C.; Faivre, L.; Frébourg, T.; Saugier.; Veber, P.; Campion, D. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch. Gen. Psychiatry, 2009, 66 (9), 947-956.
69. Meechan, D. W.; Tucker, E. S.; Maynard, T. M.; LaMantia, A. S. Diminished dosage of 22q11 genes disrupts neurogenesis and cortical development in a mouse model of 22q11 deletion/DiGeorge syndrome. Proc. Natl. Acad. Sci. USA, 2009, 106 (38), 16434-16445.
70. Prasad, S. E.; Howley, S. Murphy, K. C. Candidate genes and the behavioral phenotype in 22q11.2 deletion syndrome. Dev. Disabil. Res. Rev., 2008, 14 (1), 26-34.
71. Vincent, J. B.; Paterson, A. D.; Strong, E.; Petronis, A.; Kennedy J. L. The unstable trinucleotide repeat story of major psychosis. Am. J. Med. Genet., 2000, 97 (1), 77-97.
72. Bruce, H. A.; Sachs, N.; Rudnicki, D. D.; Lin, S. G.; Willour, V. L.; Cowell, J. K.; Conroy, J.; McQuaid, D. E.; Rossi, M.; Gaile, D. P.; Nowak, N. J.; Holmes, S. E.; Sklar, P.; Ross, C. A.; Delisi, L. E.; Margolis, R. L. Long tandem repeats as a form of genomic copy number variation: structure and length polymorphism of a chromosome 5p repeat in control and schizophrenia populations. Psychiatr. Genet., 2009, 19 (2), 64-71.
73. Hamshere, M. L.; Schulze, T. G.; Schumacher, J.; Corvin, A.; Owen, M. J.; Jamra, R. A.; Propping, P.; Maier, W.; Orozco y Diaz, G.; Mayoral, F.; Rivas, F.; Jones, I.; Jones, L.; Kirov, G.; Gill, M.; Holmans, P. A.; Nöthen, M. M.; Cichon, S.; Rietschel, M.; Craddock, N. Mood-incongruent psychosis in bipolar disorder: conditional linkage analysis shows genome-wide suggestive linkage at 1q32.3, 7p13 and 20q13.31. Bipolar Disord., 2009, 11 (6), 610-620.
74. Shaffer, L. G.; Theisen, A.; Bejjani, B. A.; Ballif, B. C.; Aylsworth, A. S.; Lim, C.; McDonald, M.; Ellison, J. W.; Kostiner, D.; Saitta, S.; Shaikh, T. The discovery of microdeletion syndromes in the post-genomic era: review of the methodology and characterization of a new 1q41q42 microdeletion syndrome. Genet. Med., 2007, 9 (9), 607-616.
75. Slavotinek, A. M. Novel microdeletion syndromes detected by chromosome microarrays. Hum. Genet., 2008, 124 (1), 1-17.
76. Glessner, J. T.; Wang, K.; Cai, G.; Korvatska, O.; Kim, C.E.; Wood, S.; Zhang, H.; Estes, A.; Brune, C. W.; Bradfield, J. P.; Imielinski, M.; Frackelton, E. C.; Reichert, J.; Crawford, E. L.; Munson, J.; Sleiman, P. M.; Chiavacci, R.; Annaiah, K.; Thomas, K.; Hou, C.; Glaberson, W.; Flory, J.; Otieno, F.; Garris, M.; Soorya, L.; Klei, L.; Piven, J.; Meyer, K. J.; Anagnostou, E.; Sakurai, T.; Game, R. M.; Rudd, D. S.; Zurawiecki, D.; McDougle, C. J.; Davis, L. K.; Miller, J.; Posey, D. J.; Michaels, S.; Kolevzon, A.; Silverman, J. M.; Bernier, R.; Levy, S. E.; Schultz, R. T.; Dawson, G.; Owley, T.; McMahon, W. M.; Wassink, T. H.; Sweeney, J. A.; Nurnberger, J. I.; Coon, H.; Sutcliffe, J. S.; Minshew, N. J.; Grant, S. F.; Bucan, M.; Cook, E. H.; Buxbaum, J. D.; Devlin, B.; Schellenberg, G. D.; Hakonarson, H. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature, 2009, 459 (7246), 569-573.
77. Bucan, M.; Abrahams, B. S.; Wang, K.; Glessner, J. T.; Herman, E. I.; Sonnenblick, L. I.; Alvarez Retuerto, A. I.; Imielinski, M.; Hadley, D.; Bradfield, J. P.; Kim, C.; Gidaya, N. B.; Lindquist, I.; Hutman, T.; Sigman, M.; Kustanovich, V.; Lajonchere, C. M.; Singleton, A.; Kim, J.; Wassink, T. H.; McMahon, W. M.; Owley, T.; Sweeney, J. A.; Coon, H.; Nurnberger Jr, J. I.; Li, M.; Cantor, R. M.; Minshew, N. J.; Sutcliffe, J. S.; Cook, E. H.; Dawson, G.; Buxbaum, J. D.; Grant, S. F. A.; Schellenberg, G. D.; Geschwind, D. H.; Hakonarson, H. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet., 2009, 5 (6), e1000536.
78. Kumar, R. A.; Christian, S. L. Genetics of autism spectrum disorders. Curr. Neurol. Neurosci. Rep., 2009, 9 (3), 188-197.
79. Yan, J.; Zhang, F.; Brundage, E.; Scheuerle, A.; Lanpher, B.; Erickson, R. P.; Powis, Z.; Robinson, H. B.; Trapane, P. L.; Stachiw-Hietpas, D.; Keppler-Noreuil, K. M.; Lalani, S. R.; Sahoo, T.; Chinault, A. C.; Patel, A.; Cheung, S. W.; Lupski, J. R. Genomic duplication resulting in increased copy number of genes encoding the sister chromatid cohesion complex conveys clinical consequences distinct from Cornelia de Lange. J. Med. Genet., 2009, 46 (9), 626-634.
80. Sun, G.; Yan, J.; Noltner, K.; Feng, J.; Li, H.; Sarkis, D. A.; Sommer, S. S.; Rossi, J. J. SNPs in human miRNA genes affect biogenesis and function. RNA, 2009, 15 (9), 1640-1651.
81. Feng, J.; Sun, G.; Yan, J.; Noltner, K.; Li, W.; Buzin, C. H.; Longmate, J.; Heston, L. L.; Rossi, J.; Sommer, S. S. Evidence for Xchromosomal schizophrenia associated with microRNA alterations. PLoS One, 2009, 4 (7), e6121.
82. Burmistrova, O. A.; Goltsov, A. Y.; Abramova, L. I.; Kaleda, V. G.; Orlova, V. A.; Rogaev, E. I. MicroRNA in schizophrenia: genetic and expression analysis of miR-130b (22q11). Biochemistry (Mosc), 2007, 72 (5), 578-582.
83. Gregory, R. I.; Chendrimada, T. P.; Shiekhattar, R. MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol. Biol., 2006, 342, 33-47.
84. Zhu, Y.; Kalbfleisch, T.; Brennan, M. D.; Li, Y. (MicroRNA gene is hosted in an intron of a schizophrenia-susceptibility gene. Schizophr. Res., 2009, 109 (1-2), 86-89.
85. Pinsonneault, J. K.; Papp, A. C.; Sadée, W. Allelic mRNA expression of X-linked monoamine oxidase A (MAOA) in human brain: dissection of epigenetic and genetic factors. Human Mol. Genet., 2006, 15 (17), 2636-2649.
86. Crews, D. Epigenetics and its implications for behavioural neuroendocrinology. Front. Neuroendocrinol, 2008, 29 (3), 344-357.
87. Feng, J.; Fan, G. The role of DNA methylation in the central nervous system and neuropsychiatric disorders. Int. Rev. Neurobiol., 2009, 89, 67-84.
88. Reichenberg, A.; Mill, J.; MacCabe, J. H. Epigenetics, genomic mutations and cognitive function. Cogn. Neuropsychiatry, 2009, 14 (4-5), 377-390.
89. MacDonald, J. L.; Roskams, A. J. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Prog. Neurobiol., 2009, 88 (3), 170-183.
90. Urdinguio, R. G.; Sanchez-Mut, J. V.; Esteller, M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol., 2009, 8 (11), 1056-1072.
91. Bronner, C.; Chataigneau, T.; Schini-Kerth, V. B.; Landry, Y. The "Epigenetic Code Replication Machinery" ECREM: a promising drugable target of the epigenetic cell memory. Curr. Med. Chem., 2007, 14 (25), 2629-2641.
92. Chavez-Blanco, A.; Pérez-Plasencia, C.; Pérez-Cárdenas, E.; Carrasco-Legleu, C.; Rangel-Lopez, E.; Segura-Pacheco, B.; Taja-Chayeb, L.; Trejo-Becerril, C.; Gonzalez-Fierro, A.; Candelaria, M.; Cabrera, G. Duenas-Gonzalez, A. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Intern., 2006, 6, 2.
93. Abdolmaleky, H. M.; Smith, C. L.; Zhou, J. R.; Thiagalingam, S. Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Meth. Mol. Biol., 2008, 448, 187-212.
94. Kazantsev, A. G.; Thompson, L. M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug. Discov., 2008, 7 (10), 854-68.
95. Dong, E.; Nelson, M.; Grayson, D. R.; Costa, E.; Guidotti, A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. USA, 2008, 105 (36), 13614-13619.
96. Guidotti, A.; Dong, E.; Kundakovic, M.; Satta, R.; Grayson, D. R.; Costa, E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci., 2009, 30 (2), 55-60.
97. Costa, E.; Chen, Y.; Dong, E.; Grayson, D. R.; Kundakovic, M.; Maloku, E.; Ruzicka, W.; Satta, R.; Veldic, M.; Zhubi, A.; Guidotti, A. GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev. Neurother., 2009, 9 (1), 87-98.
98. Dong, E.; Agis-Balboa, R. C.; Simonini, M. V.; Grayson, D. R.; Costa, E.; Guidotti, A. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc. Natl. Acad. Sci. USA, 2005, 102 (35), 12578-12583.
99. Grayson, D. R.; Chen, Y.; Dong, E.; Kundakovic, M.; Guidotti, A. From trans-methylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia. Epigenetics, 2009, 4 (3), 144-149.
100. Gavin, D. P.; Kartan, S.; Chase, K.; Jayaraman, S.; Sharma, R. P. Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J. Psychiatr. Res., 2009, 43 (9), 870-876.
101. Rezin, G. T.; Amboni, G.; Zugno, A. I.; Quevedo, J.; Streck E. L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res., 2009, 34 (6), 1021-1029.
102. Shao, L.; Martin, M. V.; Watson, S. J.; Schatzberg, A.; Akil, H.; Myers, R. M.; Jones, E. G.; Bunney, W. E.; Vawter, M. P. Mitochondrial involvement in psychiatric disorders. Ann. Med., 2008, 40 (4), 281-295.
103. Rollins, B.; Martin, M. V.; Sequeira, P. A.; Moon, E. A.; Morgan, L. Z.; Watson, S. J.; Schatzberg, A.; Akil, H.; Myers, R. M.; Jones, E. G.; Wallace, D. C.; Bunnery, W. E.; Vawter, M. P. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS One, 2009, 4 (3), e4913.
104. Munakata, K.; Iwamoto, K.; Bundo, M.; Kato, T. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol. Psychiatry, 2005, 57 (5), 525-532.
105. Washizuka, S.; Iwamoto, K.; Kakiuchi, C.; Bundo, M.; Kato, T. Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. Neurosci. Res., 2009, 63 (3), 199-204.
106. Cacabelos, R. Pharmacogenomics in Alzheimer's disease. Meth. Mol. Biol., 2008, 448, 213-357.
107. Bilder, R. M.; Sabb, F. W.; Parker, D. S.; Kalar, D.; Chu, W. W.; Fox, J.; Freimer, N. B.; Poldrack, R. A. Cognitive ontologies for neuropsychiatric phenomics research. Cogn. Neuropsychiatry, 2009, 14 (84), 419-450.
108. Meda, S. A.; Jagannathan, K.; Gelernter, J.; Calhoun, V. D.; Liu, J.; Stevens, M. C.; Pearlson, G. D. A pilot multivariate parallel ICA study to investigate differential linkage between neural networks and genetic profiles in schizophrenia. Neuroimage, 2010, 53 (3), 1007-1015.
109. Bergen, S. E.; Fanous, A. H.; Walsh, D.; O'Neill, F. A.; Kendler, K. S. Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. Schizophr. Res., 2009, 109 (1-3), 94-97.
110. Chu, T. T.; Liu, Y.; Kemether, E. Thalamic transcriptome screening in three psychiatric states. J. Hum. Genet., 2009, 54 (11), 665-675.
111. Dean, B.; Boer, S.; Gibbons, A.; Money, T.; Scarr, E. Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr. Opin. Psychiatry, 2009, 22 (2), 154-60.
112. Martins-de-Souza, D.; Gattaz, W. F.; Schmitt, A.; Novello, J. C.; Marangoni, S.; Turck, C. W.; Dias-Neto, E. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry, 2009, 9, 17.
113. Kuzman, M. R.; Medved, V.; Terzic, J.; Krainc, D. Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia. J. Psychiatr. Res., 2009, 43 (13), 1073-1077.
114. Quinones, M. P.; Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis., 2009, 35 (2), 165-176.
115. Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health, 2005, 1, 303-348.
116. Cacabelos, R.; Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future, 2006, 31 (Suppl B), 5-146.
117. Roses, A. D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet., 2004, 5 (9), 645-656.
118. Verrils, N. M. Clinical proteomics: Present and future prospects. Clin. Biochem. Rev., 2006, 27 (2), 99-116.
119. Doshi, J. A.; Shaffer, T.; Briesacher, B. A. National estimates of medication use in nursing homes: Findings from 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. J. Am. Geriatr. Soc., 2005, 53 (3), 438-443.
120. Fialová, D.; Topinková, E.; Gambassi, G.; Finne-Soveri, H.; Jónsson, P. V.; Carpenter, I.; Schroll, M.; Onder, G.; Sørbye, L. W.; Wagner, C.; Reissigová, J.; Bernabei, R. the AdHOC Project Research Group. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA, 2005, 293 (11), 1348-1358.
121. Simon, S. R.; Chan, K. A.; Soumerai, S. B.; Wagner, A. K.; Andrade, S. E.; Feldstein, A. C.; Lafata, J. E.; Davis, R. L. Gurwitz, J. K. Potentially inappropriate medication use by elderly persons in U.S. Health Maintenance Organizations, 2000-2001. J. Am. Geriatr. Soc., 2005, 53 (2), 227-232.
122. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med., 2003, 348 (6), 529-537.
123. Berry, N.; Jobanputra, V. Pal, H. Molecular genetics of schizophrenia: a critical review. J. Psychiatry Neurosci., 2003, 28 (6), 415-429.
124. Kato, T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin. Neurosci., 2007, 61 (1), 3-19.
125. Cacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med., 2002, 34 (5), 357-79.
126. Cacabelos, R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics, 2003, 4 (5), 597-621.
127. Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp. Opin. Pharmacother., 2005, 6 (12), 1967-1987.
128. Cacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258 (Suppl1), 28-47.
129. Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol. Diag. Ther., 2007, 11 (6), 385-405.
130. Cacabelos, R.; Llovo, R.; Fraile, C.; Fernández-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr. Alzheimer Res., 2007, 4 (4), 479-500.
131. Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol., 2007, 29 (Suppl B), 1-91.
132. Cacabelos, R.; Fernández-Novoa, L.; Pichel, V.; Lombardi, V.; Kubota, Y.; Takeda, M. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In Molecular Neurobiology of Alzheimer Disease and Related Disorders, Takeda, M.; Tanaka, T.; Cacabelos, R. eds.; Karger, Basel, 94-107, 2004.
133. Cacabelos R. Pharmacogenomics in Alzheimer's disease. In: Pharmacogenomics and Personalized Medicine, Cohen, N. ed.; Humana Press, NJ, 317-368, 2008.
134. Zhou, S. F.; Di, Y. M.; Chan, E.; Du, Y. M.; Chow, V. D.; Xue, C. C.; Lai, X.; Wang, J. C.; Li, C. G.; Tian, M.; Duan, W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab., 2008, 9 (8), 738-784.
135. Williams, J. A.; Andersson, T.; Andersson, T. B.; Blanchard, R.; Behm, M. O.; Cohen, N.; Edeki, T.; Franc, M.; Hillgren, K. M.; Johnson, K. J.; Katz, D. A.; Milton, M. N.; Murray, B. P.; Polli, J. W.; Ricci, D.; Shipley, L. A.; Vangala, S.; Wrighton, S. A. PhRMA White Paper on ADME Pharmacogenomics. J. Clin. Pharmacol., 2008, 48, 849-889.
136. Pai, H. V.; Kommaddi, R. P.; Chinta, S. J.; Mori, T.; Boyd, M. R.; Ravindranath, V. J. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J. Biol. Chem., 2004, 279 (26), 27383-27389.
137. Cacabelos, R. World Guide for Drug Use and Pharmacogenomics. EuroEspes Publishing ed, Corunna, Spain In Press, 2010.
138. Zanger, U. M.; Turpeinen, M.; Klein, K.; Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem., 2008, 392 (6), 1093-1108.
139. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se. (Accessed May 21, 2010).
140. The Pharmacogenomics Knowledge Base. Available at: http://www.pharmgkb.org. (Accessed May 21, 2010).
141. Frank, D.; Jaehde, U. Fuhr, U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol., 2007, 63 (4), 321-333.
142. Shen, H.; He, M. M.; Liu, H.; Wrighton, S. A.; Wang, L.; Guo, B.; Li, C. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 2007, 35(8), 1292-1300.
143. Ozawa, S.; Soyama, A.; Saeki, M.; Fukushima-Uesaka, H.; Itoda, M.; Koyano, S.; Sai, K.; Ohno, Y.; Saito, Y.; Sawada, J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokin., 2004, 19 (2), 83-95.
144. Sachse, C.; Brockmoller, J.; Bauer, S.; Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 1997, 60 (2), 284-295.
145. Weinshilboum, R. M.; Wang, L. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu. Rev. Genomics Hum. Genet., 2006, 7, 223-245.
146. Miksys, S. L.; Tyndale, R. F. Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci., 2002, 27 (6), 406-415.
147. Siegle, I.; Fritz, P.; Eckhardt, K.; Zanger, U. M.; Eichelbaum, M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics, 2001, 11(3), 237-245.
148. Pilotto, A.; Franceschi, M.; D'Onofrio, G.; Bizzarro, A.; Mangialasche, F.; Cascavilla, L.; Paris, F.; Matera, M. G.; Pilotto, A.; Daniele, A.; Mecocci, P.; Masullo, C.; Dallapiccola, B.; Seripa, D. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology, 2009, 73 (10), 761-767.
149. Lamba, J. K.; Lin, Y. S.; Schuetz, E. G.; Thummel, K. E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev., 2002, 54 (10), 1271-1294.
150. Voirol, P.; Jonzier-Perey, M.; Porchet, F.; Reymond, M. J.; Janzer, R. C.; Bouras, C.; Strobel, H. W.; Kosel, M.; Eap, C. B.; Baumann, P. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res., 2002, 855 (2), 235-243.
151. Agarwal, V.; Kommaddi, R. P.; Valli, K.; Ryder, D.; Hyde, T. M.; Kleinman, J. E.; Strobel, H. W.; Ravindranath, V. Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One, 2008, 3 (6), e2337.
152. Ghosh, C.; Gonzalez-Martinez, J.; Hossain, M.; Cucullo, L.; Fazio, V.; Janigro, D.; Marchi, N. Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow. Epilepsia, 2010, 51 (8), 1408-1417.
153. Cacabelos, R.; Fernández-Novoa, L.; Lombardi, V.; Kubota, Y.; Takeda, M. Molecular genetics of Alzheimer's disease and aging. Meth. Find. Exper. Clin. Pharmacol., 2005, 27 (Suppl A), 1-573.
154. Takeda, M.; Martínez, R.; Kudo, T.; Tanaka, T.; Okochi, M.; Tagami, S.; Morihara, T.; Hashimoto, R.; Cacabelos, R. Apolipoprotein E and central nervous system disorders: reviews of clinical findings. Psychiatry Clin. Neurosci., 2010, 64 (6), 592-607.
155. Thomann, P. A.; Roth, A. S.; Dos Santos, V.; Toro, P.; Essig, M.; Schröder, J. Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment. Dement. Geriatr. Cogn. Disord., 2008, 26 (4), 300-305.
156. Sando, S. B.; Melquist, S.; Cannon, A.; Hutton, M. L.; Sletvold, O.; Saltvedt, I.; White, L. R.; Lydersen, S.; Aasly, J. O. APOEε4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. BMC Neurol., 2008, 8, 9.
157. Roses, A. D. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLAB(*) 5701 as a model of safety. Neuropsychopharmacology, 2009, 34, 6-17.
158. Roses, A. D.; Saunders, A. M.; Huang, Y.; Strum, J.; Weisgraber, K. H.; Mahley, R. W. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenic hypothesis (Alzheimer's disease). Pharmacogenomics J., 2007, 7 (1), 10-28.
159. Risner, M. E.; Saunders, A. M.; Altman, J. F.; Ormandy, G. C.; Craft, S.; Foley, I. M.; Zvartau-Hind, M. E.; Hosford, D. A.; Roses, A. D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J., 2006, 6 (4), 246-254.
160. Malhotra, A. K.; Lencz, T.; Correll, C. U.; Kane, J. M. Genomics and the future of pharmacotherapy in psychiatry. Int. Rev. Psychiatry, 2007, 19 (5), 523-530.
161. Nnadi, C. U.; Malhorta, A. K. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr. Psychiatry Rep., 2007, 9 (4), 313-318.
162. Foster, A.; Miller, D.; Buckley, P. F. Pharmacogenetics and schizophrenia. Psychiatr. Clin. North Am., 2007, 30 (3), 417-435.
163. Arranz, M. J.; de Leon, J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry, 2007, 12 (8), 707-747.
164. Mizutani, T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev., 2003, 35 (2-3), 99-106.
165. Xie, H. G.; Prasad, H. G.; Kim, R. B.; Stein, C. M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev., 2002, 54 (10), 1257-1270.
166. Isaza, C. A.; Henao, J.; López, A. M.; Cacabelos, R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 2000, 22 (9), 695-705.
167. Xie, H. G.; Kim, R. B.; Wood, A. J.; Stein, C. M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharm. Toxicol., 2001, 41, 815-850.
168. Madan, A.; Graham, R. A.; Carroll, K. M.; Mudra, D. R.; Burton, L. A.; Krueger, L. A.; Downey, A. D.; Czerwinski, M.; Forster, J.; Ribadeneira, M. D.; Gan, L. S.; LeCluyse, E. L.; Zech, K.; Robertson, P. Jr; Koch, P.; Antonian, L.; Wagner, G.; Yu, L.; Parkinson, A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos., 2003, 31 (4), 421-431.
169. Hedlund, E.; Gustafsson, J. A.; Warner, M. Cytochrome P450 in the brain: a review. Curr. Drug Metabol., 2001, 2 (3), 245-263.
170. Funae, Y.; Kishimoto, W.; Cho, T.; Niwa, T.; Hiroi, T. CYP2D in the brain. Drug Metab. Pharmacokin., 2003, 18 (6), 337-349.
171. Scordo, M. G.; Spina, E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics, 2002, 3 (2), 201-218.
172. Ingelman-Sundberg, M.; Sim, S. C.; Gomez, A.; Rodríguez-Antona, C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 2007, 116 (3), 496-526.
173. Shin, J. G.; Soukhova, N.; Flockhart, D. A. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab. Dispos., 1999, 27 (9), 1078-1084.
174. Urichuk, L.; Prior, T. I.; Dursun, S.; Baker, G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab., 2008, 9 (5), 410-418.
175. Kobylecki, C. J.; Jakobsen, K. D.; Hansen, T.; Jakobsen, I. V.; Rasmussen, H. B.; Werge, T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology, 2009, 59 (4), 222-226.
176. Kang, R. H.; Jung, S. M.; Kim, K. A.; Lee, D. K.; Cho, H. K.; Jung, B. J.; Kim, Y. K.; Kim, S. H.; Han, C.; Lee, M. S.; Park, J. Y. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J. Clin. Psychopharmacol., 2009, 29 (3), 272-277.
177. Yagihashi, T.; Mizuno, M.; Chino, B.; Sato, Y.; Sakuma, K.; Takebayashi, T.; Takao, T.; Kosaki, K. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum. Psychopharmacol., 2009, 24 (4) 301-308.
178. Fleeman, N.; McLeod, C.; Bagust, A.; Beale, S.; Boland, A.; Dundar, Y.; Jorgensen, A.; Payne, K.; Pirmohamed, M.; Pushpakom, S.; Walley, T.; de Warren-Penny, P.; Dickson, R. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol. Assess., 2010, 14 (3), 1-182.
179. Buchanan, R. W.; Freedman, R.; Javitt, D. C.; Abi-Dargham, A.; Lieberman, J. A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull., 2007, 33 (5), 1120-1130.
180. Tamminga, C. A. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry, 2006, 67 (9), e11.
181. Malhotra, A. K.; Murphy, G. M. Jr.; Kennedy, J. L. Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry, 2004, 161 (5), 780-796.
182. de Leon, J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol. Res., 2009, 59 (2), 81-89.
183. Need, A. C.; Keefe, R. S.; Ge, D.; Grossman, I.; Dickson, S.; McEvoy, J. P.; Goldstein, D. B. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet., 2009, 17 (7), 946-957.
184. Ikeda, M.; Tomita, Y.; Mouri, A.; Koga, M.; Okochi, T.; Yoshimura, R.; Yamanouchi, Y.; Kinoshita, Y.; Hashimoto, R.; Williams, H. J.; Takeda, M.; Nakamura, J.; Nabeshima, T.; Owen, M. J.; O'Donovan, M. C.; Honda, H.; Arinami, T.; Ozaki, N.; Iwata, N. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol. Psychiatry, 2010, 67 (3), 263-269.
185. Iwahashi, K.; Murayama, O.; Aoki, J.; Watanabe, M.; Ishigouoka, J. Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine. Nihon Shinkei Seishin Yakurigaku Zasshi, 2009, 29 (4), 141-144.
186. Wei, Z.; Wang, L.; Xuan, J.; Che, R.; Du, J.; Qin, S.; Xing, Y.; Gu, B.; Yang, L.; Li, H.; Li, J.; Feng, G.; He, L.; Xing, Q. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33 (3), 547-551.
187. Chen, S. F.; Shen, Y. C.; Chen, C. H. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33 (3), 470-474.
188. Chen, S. F.; Shen, Y. C.; Chen, C. H. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl), 2009, 205 (2), 285-292.
189. Park, S. W.; Lee, J. G.; Ha, E. K.; Choi, S. M.; Cho, H. Y.; Seo, M. K.; Kim, Y. H. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur. Neuropsychopharmacol., 2009, 19 (5), 356-362.
190. Zuo, L.; Luo, X.; Krystal, J. H.; Cramer, J.; Charney, D. S. and Gelernter, J. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet. Genomics, 2009, 19 (6), 437-446.
191. Fatemi, S. H.; Reutiman, T. J.; Folsom, T. D. Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophr. Res., 2009, 111 (1-3), 138-152.
192. Cashman, J. R.; Zhang, J.; Nelson, M. R.; Braun, A. Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine. Drug Metab. Lett., 2008, 2 (2), 100-114.
193. Gupta, M.; Bhatnagar, P.; Grover, S.; Kaur, H.; Baghel, R.; Bhasin, Y.; Chauhan, C.; Verma, B.; Manduva, V.; Mukherjee, O.; Purushottam, M.; Sharma, A.; Jain, S.; Brahmachari, S. K.; Kukreti, R. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics, 2009, 10 (3), 385-397.
194. Herken, H.; Erdal, M.; Aydin, N.; Sengul, C.; Karadag, F.; Barlas, O.; Akin, F. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol., 2009, 28 (10), 515-519.
195. Ujike, H.; Nomura, A.; Morita, Y.; Morio, A.; Okahisa, Y.; Kotaka, T.; Kodama, M.; Ishihara, T. Kuroda, S. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J. Clin. Psychiatry, 2008, 69 (9), 1416-1422.
196. Basile, V. S.; Masellis, M.; McIntyre, R. S.; Meltzer, H. Y.; Lieberman, J. A.; Kennedy, J. L. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatry, 2001, 62 (Suppl 23), 45-66.
197. Gunes, A.; Melkersson, K. I.; Scordo, M. G.; Dahl, M. L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J. Clin. Psychopharmacol., 2009, 29 (1), 65-68.
198. Gregoor, J. G.; van der Weide, J.; Mulder, H.; Cohen, D.; van Megen, H. J.; Egberts, A. C.; Heerdink, E. R. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J. Clin. Psychopharmacol., 2009, 29 (1), 21-25.
199. Mulder, H.; Cohen, D.; Scheffer, H.; Gispen-de Wied, C.; Arends, J.; Wilmink, F. W.; Franke, B.; Egberts, A. C. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol., 2009, 29 (1), 16-20.
200. Kwon, J. S.; Joo, Y. H.; Nam, H. J.; Lim, M.; Cho, E. Y.; Jung, M. H.; Choi, J. S.; Kim, B.; Kang, D. H.; Oh, S.; Park, T.; Hong, K. S. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch. Gen. Psychiatry, 2009, 66 (11), 1233-1241.
201. Volpi, S.; Potkin, S. G.; Malhotra, A. K.; Licamele, L.; Lavedan, C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry, 2009, 70 (6), 801-809.
202. Choi, K. H.; Higgs, B. W.; Weis, S:, Song, J.; Llenos, I. C.; Dulay, J. R.; Yolken, R. H.; Webster, M. J. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry, 2009, 9, 57.
203. Chana, G.; Lucero, G.; Salaria, S.; Lozach, J.; Du, P.; Woelk, C.; Everall, I. Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. Schizophr. Res., 2009, 113 (2-3), 273-276.
204. Ji, B.; La, Y.; Gao, L.; Zhu, H.; Tian, N.; Zhang, M.; Yang, Y.; Zhao, X.; Tang, R.; Ma, G.; Zhou, J.; Meng, J.; Ma, J.; Zhang, Z.; Li, H.; Feng, G.; Wang, Y.; He, L.; Wan, C. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J. Proteome Res., 2009, 8 (7), 3633-3641.
205. Ma, D.; Chan, M. K.; Lockstone, H. E.; Pietsch, S. R.; Jones, D. N.; Cilia, J.; Hill, M. D.; Robbins, M. J.; Benzel, I. M.; Umrania, Y.; Guest, P. C.; Levin, Y.; Maycox, P. R.; Bahn, S. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J. Proteome Res., 2005, 8 (7), 3284-3297.
206. Dell'aversano, C.; Tomasetti, C.; Iasevoli, F.; de Bartolomeis, A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Res. Bull., 2009, 79 (2), 123-129.
207. Murphy, G. M. Jr; Kremer, C.; Rodrigues, H. E.; Schatzberg, A. F. Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry, 2003, 160 (10),1830-1835.
208. Grasmäder, K.; Verwohlt, P. L.; Rietschel, M.; Dragicevic, A.; Müller, M.; Hiemke, C.; Freymann, N.; Zobel, A.; Maier, W.; Rao, M. L. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur. J. Clin. Pharmacol., 2004, 60 (5), 329-336.
209. Ereshefsky, L.; Riesenman, C.; Lam, Y. W. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin. Pharmacokinet., 1995, 29 (Suppl 1), 10-18.
210. Bijl, M. J.; Visser, L. E.; Hofman, A.; Vulto, A. G.; van Gelder, T.; Stricker, B. H.; van Schaik, R. H. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br. J. Clin. Pharmacol., 2008, 65 (4), 558-564.
211. Baumann, P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet., 2006, 31 (6), 444-469.
212. Preskorn, S. H.; Shah, R.; Neff, M.; Golbeck, A. L.; Choi, J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J. Psychiatr. Pract., 2007, 13 (1), 5-12.
213. Sproule, B. A.; Naranjo, C. A.; Brenmer, K. E.; Hassan, P. C. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin. Pharmacokinet., 1997, 33 (6), 454-471.
214. Spigset, O.; Hedenmalm, K.; Dahl, M. L.; Wiholm, B. E.; Dahlqvist, R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr. Scand., 1997, 96 (5), 379-384.
215. Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere, M. L.; Pahwa, J. S.; Moskvina, V.; Dowzell, K.; Williams, A.; Jones, N.; Thomas, C.; Stretton, A.; Morgan, A. R.; Lovestone, S.; Powell, J.; Proitsi, P.; Lupton, M. K.; Brayne, C.; Rubinsztein, D. C.; Gill, M.; Lawlor, B.; Lynch, A.; Morgan, K.; Brown, K. S.; Passmore, P. A.; Craig, D.; McGuinness, B.; Todd, S.; Holmes, C.; Mann, D.; Smith, A. D.; Love, S.; Kehoe, P. G.; Hardy, J.; Mead, S.; Fox, N.; Rossor, M.; Collinge, J.; Maier, W.; Jessen, F.; Schürmann, B.; van den Bussche, H:, Heuser, I.; Kornhuber, J.; Wiltfang, J.; Dichgans, M.; Frölich, L.; Hampel, H.; Hüll, M.; Rujescu, D.; Goate, A. M.; Kauwe, J. S.; Cruchaga, C.; Nowotny, P.; Morris, J. C.; Mayo, K.; Sleegers, K:, Bettens, K.; Engelborghs, S.; De Deyn, P. P.; Van Broeckhoven, C.; Livingston, G.; Bass, N. J.; Gurling, H.; McQuillin, A.; Gwilliam, R.; Deloukas, P.; Al-Chalabi, A.; Shaw, C. E.; Tsolaki, M.; Singleton, A. B.; Guerreiro, R.; Mühleisen, T. W.; Nöthen, M. M.; Moebus, S.; Jöckel, K. H.; Klopp, N.; Wichmann, H. E.; Carrasquillo, M. M.; Pankratz, V. S.; Younkin, S. G.; Holmans, P. A.; O'Donovan, M.; Owen, M. J.; Williams, J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet., 2009, 41 (10), 1088-1093.
216. Lambert, J. C.; Heath, S.; Even, G.; Campion, D.; Sleegers, K.; Hiltunen, M.; Combarros, O.; Zelenika, D.; Bullido, M. J.; Tavernier, B.; Letenneur, L.; Bettens, K.; Berr, C.; Pasquier, F.; Fiévet, N.; Barberger-Gateau, P.; Engelborghs, S.; De Deyn, P.; Mateo, I.; Franck, A.; Helisalmi, S.; Porcellini, E.; Hanon, O.; European Alzheimer's Disease Initiative Investigators, de Pancorbo, M. M.; Lendon, C.; Dufouil, C.; Jaillard, C.; Leveillard, T.; Alvarez, V.; Bosco, P.; Mancuso, M.; Panza, F.; Nacmias, B.; Bossù, P.; Piccardi, P.; Annoni, G.; Seripa, D.; Galimberti, D.; Hannequin, D.; Licastro, F.; Soininen, H.; Ritchie, K.; Blanché, H.; Dartigues, J. F.; Tzourio, C.; Gut, I.; Van Broeckhoven, C.; Alpérovitch, A.; Lathrop, M.; Amouyel, P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet., 2009, 41 (10), 1094-1099.
217. van Steen, K.; McQueen, M. B.; Herbert, A.; Raby, B.; Lyon, H.; Demeo, D. L.; Murphy, A.; Su, J.; Datta, S.; Rosenow, C.; Christman, M.; Silverman, E. K.; Laird, N. M.; Weiss, S. T.; Lange, C. Genomic screening and replication using the same data set in family-based association testing. Nat. Genet., 2005, 37 (7), 683-691.
218. Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med., 2006, 57, 119-137.
219. Sowell, R. A.; Owen, J. B.; Butterfield, D. A. Proteomics in animal models of Alzheimer's and Parkinson's disease. Ageing Res. Rev., 2009, 8 (1), 1-17.
220. Khachaturian, Z. S.; Petersen, R. C.; Gauthier, S.; Buckholtz, N.; Corey-Bloom, J. P.; Evans, B.; Fillit, H.; Foster, N.; Greenberg, B.; Grundman, M.; Sano, M.; Simpkins, J.; Schneider, L. S.; Weiner, M. W.; Galasko, D.; Hyman, B.; Kuller, L.; Schenk, D.; Snyder, S.; Thomas, R. G.; Tuszynski, M. H.; Vellas, B.; Wurtman, R. J.; Snyder, P. J.; Frank, R. A.; Albert, M.; Doody, R.; Ferris, S.; Kaye, J.; Koo, E.; Morrison-Bogorad, M.; Reisberg, B.; Salmon, D. P.; Gilman, S.; Mohs, R.; Aisen, P. S.; Breitner, J. C.; Cummings, J. L.; Kawas, C.; Phelps, C.; Poirier, J.; Sabbagh, M.; Touchon, J.; Khachaturian, A. S.; Bain, L. J. A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. Alzheimers Dement., 2008, 4 (3), 156-163.
221. Cacabelos, R. Role of nutrition in the prevention of Alzheimer's disease. Aging Health, 2005, 1 (3), 359-362.
222. Need, A. C.; Motulsky, A. G.; Goldstein, D. B. Priorities and standards in pharmacogenetic research. Nat. Genet., 2005, 37 (7), 671-681.
223. Johnson, A. D.; Wang, S.; Sadee, W. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol. Ther., 2005, 106 (1), 19-38.
224. Ishikawa, T.; Onishi, Y.; Hirano, H.; Oosumi, K.; Nagakura, M.; Tarui, S. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (Pglycoprotein/ MDR1). Biol. Pharm. Bull., 2004, 27 (7), 939-948.
225. Nishimura, M.; Naito, S. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab. Pharmacokin., 2008, 23 (1), 22-44.
226. Agrawal, N.; Dasaradhi, P. V.; Mohmmed, A.; Malhotra, P.; Bhatnagar, R. K.; Mukherjee, S. K. RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev., 2003, 67 (4), 657-685.
227. Spänkuch, B.; Strebhardt, K. RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy. Curr. Pharm. Des., 2005, 11 (26), 3405-3419.
228. Leung, R. K.; Whittaker, P. A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther., 2005, 107 (2), 222-239.
229. Ying, S. Y.; Lin, S. L. Intron-mediated RNA interference and microRNA biogenesis. Methods Mol. Biol., 2009, 487, 387-413.
230. Gonzalez-Alegre, P. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol. Ther., 2007, 114 (1), 34-55.
231. Aagaard, L.; Rossi, J. J. RNA therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev., 2007, 59 (2-3) 75-86.
232. Hébert, S. S.; Horré, K.; Nicolaï, L.; Bergmans, B.; Papadopoulou, A. S.; Delacourte, A.; De Strooper, B. MicroRNA regulation of Alzheimer's amyloid precursor protein expression. Neurobiol. Dis., 2009, 33 (3), 422-428.
233. Feng, Z.; Zhao, G.; Yu, L. Neural stem cells and Alzheimer's disease: challenges and hope. Am. J. Alzheimers Dis. Other Demen., 2009, 24 (1), 52-57.